07:44 AM EDT, 09/25/2024 (MT Newswires) -- Eli Lilly ( LLY ) said Wednesday that results from a long-term study showed that more than 80% of adults and adolescents receiving monthly maintenance dosing of Ebglyss to treat moderate-to-severe atopic dermatitis maintained clear or almost-clear skin for up to three years.

The long-term study evaluating the safety and efficacy of Ebglyss also found that 83% of those treated monthly did not need high-potency topical corticosteroids or systemic treatments during the three-year study, according to the company.

Eli Lilly ( LLY ) further said that no new safety signals were observed during the study and the safety profile of the patients taking Ebglyss was consistent with previous studies.

Ebglyss was approved by the US Food and Drug Administration earlier in September.

Price: 928.85, Change: +4.42, Percent Change: +0.48